medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2014, Number 2

<< Back Next >>

Rev Invest Clin 2014; 66 (2)

Prevalence of thyroid function test abnormalities and anti-thyroid antibodies in an open population in Central México

Robles-Osorio ML, Zacarías-Rangel V, García-Solís P, Hernández-Montiel HL, Solís JC, Sabath E

Language: English
References: 29
Page: 113-120
PDF size: 157.85 Kb.


ABSTRACT

Objective. To examine the prevalence of abnormal thyroid function tests and positive anti-thyroid antibodies in two Central Mexican cities. Material and methods. Subjects 18 to 70 years old were randomly selected to participate in this survey. A questionnaire was given and blood samples were taken to measure TSH and free T4 levels as well as anti-TPO and anti- Tg antibodies. Results. The mean TSH level in subjects without existing thyroid disease was 1.72 mIU/L; 0.64 and 3.74 mIU/L were the 2.5th and 97.5th percentiles. The mean free T4 level was 1.02 ng/dL, and the 2.5th and 97.5th percentiles were 0.78 and 1.31 ng/dL, respectively. There was a 2.5% prevalence of former diagnosed thyroid diseases, 3.9% of individuals were sub-hypo, and 1.1% had overt hypothyroidism. Total hypothyroidism prevalence was 7.48% (when we considered TSH levels greater than 4.5 mIU/L), but it was 11.03% when diagnosed with TSH values greater than 3.5 mIU/L. Factors associated with hypothyroidism were older age, positive family background of thyroid disease, and positive anti- TPO and anti-Tg antibodies. Subclinical and overt hyperthyroidism were found in 1.7% of participants. Conclusions. Abnormal thyroid function test prevalence in this population was high, but few participants were aware of having a thyroid disease. The prevalence of positive anti-thyroid antibodies was high. More studies are necessary to elucidate the effects of thyroid abnormalities on other aspects of health status and quality of life.


REFERENCES

  1. 1 Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977; 7: 481-93.

  2. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANESIII). J Clin Endocrinol Metab 2002; 87: 489-99.

  3. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000; 160: 526-34.

  4. Takeda K, Mishiba M, Sugiura H, Nakajima A, Kohama M, Hiramatsu S. Evaluated reference intervals for serum free thyroxine and thyrotropin using the conventional outliner rejection test without regard to presence of thyroid antibodies and prevalence of thyroid dysfunction in Japanese subjects. Endocr J 2009; 56: 1059-66.

  5. Londoño AL, Gallego ML, Bayona A, Landázuri P. Prevalencia de hipotiroidismo y relación con niveles elevados de anticuerpos antiperoxidasa y yoduria en población de 35 y más años en Armenia 2009-2010. Rev Salud Publica 2011; 13: 998-1013.

  6. Garduño-García JJ, Alvirde-García U, López-Carrasco G, Padilla- Mendoza ME, Mehta R, et al. TSH and free thyroxine concentrations are associated with differing metabolic markers in euthyroid subjects. Eur J Endocrinol 2011; 163: 273-8.

  7. Rodondi N, den Elzen WP, Bauer DC, Cappola AR, Razvi S, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 2010; 304: 1365-74.

  8. Gencer B, Collet TH, Virgini V, Bauer DC, Gussekloo J, et al. Subclinical thyroid dysfunction and the risk of heart failure events. An individual participant data analysis from 6 prospective cohorts. Circulation 2012; 120: 1040-9.

  9. Shin DH, Lee MJ, Kim SJ, Oh HJ, Han JH, et al. Preservation of renal function by thyroid hormone replacement therapy in chronic kidney disease patients with subclinical hypothyroidism. J Clin Endocrinol Metab 2012; 97: 2732-40.

  10. Gussekloo J, van Exel E, de Craen AJM, Meinders AE, Frölich M, et al. Thyroid status, disability and cognitive function, and survival in old age. JAMA 2004; 292: 2591-9.

  11. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004; 291: 228-38.

  12. Bauer DC, Ettinger B, Nevitt MC, Stone KL. Study of osteoporotic fractures research group, risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 2001; 134: 561-8.

  13. Lee JS, Buzkova P, Fink HA, Vu J, Carbone L, et al. Subclinical thyroid dysfunction and incident hip fracture in older adults. Arch Intern Med 2010; 170: 1876-83.

  14. Selmer C, Bjerring-Olesen J, Lock-Hansen M, Lindhardsen J, Schjerning-Olsen AM, et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ 2012; 345: e7895.

  15. Benseñor IM, Lotufo PA, Menezes PR, Scazufca M. Subclinical hyperthyroidism and dementia: the Sao Paulo Ageing and Health Study (SPAH). BMC Public Health 2010; 10: 298.

  16. Zulewski H, Müller B, Exer P, Miserez, A, Staub JJ. Estimation of tissue hypothyroidism by a new clinical score: Evaluation of patients with various grades of hypothyroidism and controls. J Clin Endocrinol Metab 1997; 82: 771-6.

  17. Rosario PW, Xavier AC, Calsolari MR. TSH reference values for adult Brazilian population. Arq Bras Endocrinol Metabol 2010; 54: 603-06.

  18. Hurtado-López LM, Basurto-Kuba E, Montes de Oca-Durán ER, Pulido-Cejudo A, Vázquez-Ortega C, et al. Prevalencia de nódulo tiroideo en el valle de México. Cir Cir 2011; 79: 114-7.

  19. 19 Ladenson PW, Singer PA, Ain KB, Bagchi N, Bigos T, et al. American Thyroid Association guidelines for detection of thyroid dysfunction. Arch Intern Med 2000; 160: 1573-5.

  20. Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologist and the American Thyroid Association. Endocr Pract 2012; 18: 988-1028.

  21. Cooper DS. Subclinical hypothyroidism. N Engl J Med 2001; 345: 260-5.

  22. Fatourechi V. Upper Limit of Normal Serum Thyroid-Stimulating Hormone: A Moving and Now an Aging Target? J Clin Endocrinol Metab 2007; 92: 1460-2.

  23. Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU. The beneficial effect of l-Thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab 2007; 92: 1715-23.

  24. Villar HC, Saconato H, Valente O, Atallah AN. Thyroid hormone replacement for subclinical hypothyroidism. Cochrane Database Syst Rev 2007; 18: CD003419.

  25. Shin DH, Lee MJ, Lee HS, Oh HJ, Kim CH, et al. Thyroid hormone replacement therapy attenuates the decline of renal function in chronic kidney disease patients with subclinical hypothyroidism. Thyroid 2013; 23: 654-61.

  26. Strieder TG, Tijssen J, Wenzel BE, Endert E, Wiersinga WM. Prediction of progression to overt hypothyroidism in female relatives of patients with autoimmune thyroid disease using the thyroid events Amsterdam (THEA) score. Arch Intern Med 2008; 168: 1657-63.

  27. Tozzoli R, Bizarro N, Tonutti E, Pradella M, Manoni F, et al. Immunoassay of anti-thyroid autoantibodies: high analytical variability in second generation methods. Clin Chem Lab Med 2002; 40: 568-73.

  28. Bjøro T, Holmen J, Krüger Ø, Midthjell K, Hunstad K, Schreiner T, Sandnes L, et al. Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Trondelag (HUNT). Eur J Endocrinol 2000; 143: 639-47.

  29. Palacios SS, Larumbe AB, Guillén-Grima F, Galofré JC. A cross-sectional study of the association between circulating TSH level and lipid profile in a large Spanish population. Clin Endocrinol (Oxf) 2013 [Epub ahead of print].




2020     |     www.medigraphic.com